Navigation Links
NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Date:9/2/2008

tages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in a Phase 1 clinical trial. The objective of the development program is to determine the ability of NGX-1998 to provide protracted pain relief from a single treatment. As a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. The goal of the NGX 1998 program is to develop a product that has the potential to be used by a broad spectrum of the physician population. NGX-1998 was previously studied in two Phase 1 studies in healthy volunteers conducted under an exploratory investigational new drug application.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of regulatory filings with respect to NeurogesX' product candidates, including for NGX-4010 the potential filing of an NDA; the potential markets for NeurogesX' product candidates and the expected benefits of NeurogesX' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... solution by swimming , ... ... U.S. Department of Energy’s (DOE) Argonne National Laboratory and Northwestern ... microgears when suspended in a solution, providing insights for design ... gears are a million times more massive than the bacteria,” ...
(Date:12/16/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, according to responses from ... briakinumab (both interleukin inhibitors) will capture 22 percent ... drug market for moderate to severe psoriasis. Among ... capturing nearly three times as much patient share ...
(Date:12/16/2009)... Special Protocol Assessment with the Food and ... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on oncology and ... its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( ... trial for perifosine (KRX-0401), the Company,s PI3K/Akt ...
(Date:12/16/2009)... LLC introduces HSP-A Soy Peptone. HSP A has been found ... ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ( ... HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, ... to improve growth rates and yields. HSP-A has been found ...
Breaking Biology Technology:Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5
... PHILADELPHIA and LYON, France, Jan. 13 ... Penn Jersey Region of American Red Cross ... an agreement concerning the GMP clinical batches ... United States.(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/DC58023LOGO ) , (Logo: ...
... for Thursday, January 15th at 1:00PM PTNEW YORK, Jan. ... ) today announced that Michael S. Weiss, the Company,s ... at the J.P. Morgan 27th Annual Healthcare Conference being ... live on Thursday, January 15th at 1:00pm PT and ...
... Pharmaceuticals, Inc. (Nasdaq: ALSE ), today announced that ... agreement (the "Agreement") with Robert Gipson for the private placement ... a purchase price of $1.00 per share. The financing ... connection with the Agreement, Mr. Gipson agreed to the cancellation ...
Other Biology Technology:ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross 2Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4
(Date:12/16/2009)... Society has announced the winners of its student travel ... at the Moscone Convention Center in San Francisco, California, ... are selected based on scientific merit, with priority given ... conference. Each awardee receives a travel grant and ... 20. , The 2010 recipients of the Student Travel ...
(Date:12/16/2009)... get psyched up for contests, but when these rituals ... down before and during events, they could be causing ... for the symptoms of an injury, not the injury ... focuses on musculoskeletal health and sports medicine. "They may ... certain level, but pain occurs for a reason. It ...
(Date:12/16/2009)... 1 iQor, a global provider of business ... InfoWorld 100 Awards Top 100 IT project ... was the first submission for iQor. ,, "We are ... companies," said Vikas Kapoor, president and CEO of iQor. ... allowing us to work faster, smarter and with the ...
Breaking Biology News(10 mins):Biophysical Society announces winners of 2010 Student Travel Awards 2Biophysical Society announces winners of 2010 Student Travel Awards 3Biophysical Society announces winners of 2010 Student Travel Awards 4NSAIDs: Take 'em early and often when competing? Think again 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Studies examine how living conditions impact reproductive health 10141 1Studies examine how living conditions impact reproductive health 10141 2Temps Inc Acquires Medical Concepts Staffing Business From Analysts International Corporation 58423 1Temps Inc Acquires Medical Concepts Staffing Business From Analysts International Corporation 58423 2Heart Patients Benefit From At Home Care Study Finds 58421 1Heart Patients Benefit From At Home Care Study Finds 58421 2
... The December 2008 issue of BioScience includes a ... the Environment, coordinated by Louis J. Guillette, Jr., of the ... in the issue is as follows: , Meeting the ... John P. Incardona, and Matthew L. Rise. , As a ...
... summer for sports, fans. World records tumbled at the ... 200m world records, knocking tenths of a second off ... the last few decades, which made marathon runner Mark ... increase in population could account for these dramatic improvements. ...
... (SRC-2) a master regulator gene called a coactivator fast ... another day without food, they will die. , The severity ... W. O,Malley, chair of molecular and cellular biology at Baylor College ... that appears in the current issue of the journal Science ...
Other Biology News:BioScience tip sheet, December 2008 2100-meter sprint world record could go as low as 9.48 seconds 2Master gene plays key role in blood sugar levels 2
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Medium for cryopreserving subcutaneous or omental preadipocytes...
Biology Products: